Updated review of Janus kinase inhibitors for the management of inflammatory bowel disease

Table 3 Tofacitinib in acute severe ulcerative colitis

Ref.	Evidence	Number of patients	Anti-TNF-experienced	Response rate
Berinstein et al[44]	Case series	4	2 patients	75%; one patient failed to respond
Berinstein et al[45]	Case control	40	100%	Lower rate of 90% colectomy compared to the control group
Uzzan et al[47]	Retrospective	55	98%	Clinical response: 40% at week 6; clinical remission: 46% at week 14; colectomy free survival 74% at 6 months
Singh et al[48]	RCT	53	Not available	Day 7 response rate of tofacitinib: 83%; need of rescue therapy lower in tofacitinib group
Honap et al[49]	Case series	7 (5 ASUC)	100%	Three patients had colectomy-free survival
Sedano et al[50]	Case report	1	100%	Complete remission
Kotwani et al[51]	Case series	4	100%	All patients had complete remission
Malakar et al[52]	Case series	8	12.5%	87.5% patients responded by the fifth day of treatment
Bercier and Niland[53]; Narula et al[54]	Case report; open label interventional trial	1, 24	100%, 33.3%	Complete remission; day-7 clinical response was seen in 58.3% with colectomy rate of 24%

ASUC: Acute severe ulcerative colitis; TNF: Tumor necrosis factor; RCT: Randomised controlled trial.